

## Household Transmission and Clinical Features of SARS-CoV-2 Infections by Age in 2 US Communities

Huong Q. McLean, PhD, MPH,<sup>a</sup> Carlos G. Grijalva, MD, MPH,<sup>b</sup> Kayla E. Hanson, MPH,<sup>a</sup> Yuwei G. Zhu, MD, MS,<sup>b</sup> Jessica E. Deyoe, MPH,<sup>c</sup> Jennifer K. Meece, PhD,<sup>a</sup> Natasha B. Halasa, MD, MPH,<sup>b</sup> James D. Chappell, MD, PhD,<sup>b</sup> Alexandra Mellis, PhD,<sup>c</sup> Carrie Reed, DSc,<sup>c</sup> Edward A. Belongia, MD,<sup>a</sup> H. Keipp Talbot, MD, MPH,<sup>b</sup> Melissa A. Rolfes, PhD<sup>c</sup>

Affiliations: <sup>a</sup>Marshfield Clinic Research Institute, Marshfield, Wisconsin; <sup>b</sup>Vanderbilt University Medical Center, Nashville, Tennessee; and <sup>c</sup>Centers for Disease Control and Prevention, Atlanta, Georgia

### Corresponding Author

Huong McLean, Marshfield Clinic Research Institute, 1000 N Oak Ave (ML2), Marshfield, WI 54449, 715-389-3444, [mclean.huong@marshfieldresearch.org](mailto:mclean.huong@marshfieldresearch.org)

### Conflict of Interest Disclosures

NH reports grants from Sanofi and Quidel. CGG reports grants from Campbell Alliance/Syneos, the National Institutes of Health, the Food and Drug Administration, the Agency for Health Care Research and Quality and Sanofi-Pasteur, and consultation fees from Pfizer, Merck, and Sanofi-Pasteur. Other authors have no conflicts of interest relevant to this article to disclose.

### Funding/Support

This study was supported by the Centers for Disease Control and Prevention, (cooperative agreements IP001078 and IP001083). Dr. Grijalva was supported in part by the National Institute for Allergy and Infectious Diseases (K24 AI148459). The work used REDCap, which is supported by CTSA award No. UL1 TR002243 from the National Center for Advancing Translational Sciences.

Role of Funder/Sponsor: Investigators at the Centers for Disease Control and Prevention contributed to the design and conduct of the study.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.

### Data Sharing Statement

Deidentified individual participant data (including data dictionaries) will be made available upon request after publication to researchers who provide a methodologically sound proposal for use in achieving the goals of the approved proposal. Proposals should be submitted to [mrolfes1@cdc.gov](mailto:mrolfes1@cdc.gov).

### Abbreviations

CDC – Centers for Disease Control and Prevention

CI – Confidence interval

GEE – General estimating equations

IQR – Interquartile range

MCHS – Marshfield Clinic Health System

OR – Odds ratio

RR – Risk ratio

rRT-PCR – Real-time reverse transcription polymerase chain reaction

SD – Standard deviation

SIR – Secondary infection risk

US – United States

VUMC – Vanderbilt University Medical Center

## ABSTRACT

**OBJECTIVES.** Examine age differences in SARS-CoV-2 transmission risk from primary cases and infection risk among household contacts, and symptoms among those with SARS-CoV-2 infection.

**METHODS.** People with SARS-CoV-2 infection in Nashville, Tennessee and central and western Wisconsin and their household contacts were followed daily for 14 days to ascertain symptoms and secondary transmission events. Households were enrolled between April 2020 and April 2021. Secondary infection risks (SIR) by age of the primary case and contacts were estimated using generalized estimating equations.

**RESULTS.** The 226 primary cases were followed by 198 (49%) secondary SARS-CoV-2 infections among 404 household contacts. Age group-specific SIR among contacts ranged from 36% to 53%, with no differences by age. SIR was lower from primary cases aged 12-17 years than from primary cases 18-49 years (risk ratio [RR] 0.42; 95% confidence interval [CI] 0.19-0.91). SIR was 55% and 45%, respectively, among primary case-contact pairs in the same versus different age group (RR 1.47; 95% CI 0.98-2.22). SIR was highest among primary case-contacts pairs aged  $\geq 65$  years (76%) and 5-11 years (69%). Among secondary SARS-CoV-2 infections, 19% were asymptomatic; there was no difference in the frequency of asymptomatic infections by age group.

**CONCLUSIONS.** Both children and adults can transmit and are susceptible to SARS-CoV-2 infection. SIR did not vary by age, but further research is needed to understand age-related differences in probability of transmission from primary cases by age.

## 1 BACKGROUND

2 While some studies suggest children (age <18 years) are less susceptible to SARS-CoV-2  
3 infection than adults,<sup>1-4</sup> other studies of household or other close contacts have found similar  
4 secondary infection rates among children and adults.<sup>5,6</sup> Variation in mixing patterns, and  
5 likelihood of exposure and detection (contact tracing and testing practices) may contribute to  
6 reported differences in children versus adults.<sup>2,7</sup> Most prior reports on SARS-CoV-2 infection in  
7 children utilized surveillance reports or contact tracing data, and were conducted early in the  
8 course of the pandemic. During that time, children were largely protected from community  
9 exposures due to non-pharmaceutical interventions, including closure of businesses and schools.  
10 Furthermore, many of those early studies were conducted in Asia, where prevention efforts and  
11 age-related interactions likely differed from those in the United States (US).<sup>1-3</sup>

12 Children tend to have less severe illness than adults,<sup>8-11</sup> but the spectrum of illness and SARS-  
13 CoV-2 transmission risk have not been fully characterized among children in US households.  
14 Furthermore, little is known about the risk in the youngest age groups. Greater understanding of  
15 age-related differences in susceptibility, transmission risk, and illness characteristics, particularly  
16 in children, is needed to guide public health recommendations on prevention of transmission and  
17 inform plans to resume in-person school attendance.

18 We previously reported on SARS-CoV-2 transmission from a prospective study of US  
19 households.<sup>12</sup> We extended those results and examined age differences in SARS-CoV-2  
20 transmission risk from primary cases and infection risk among household contacts. We also  
21 assessed age-specific differences in symptoms and illness duration among secondary cases.  
22

## 23    **METHODS**

24    **Design, setting, and participants.** This analysis used systematically and frequently collected  
25    data from a prospective case-ascertained household SARS-CoV-2 transmission study conducted  
26    in Tennessee and Wisconsin.<sup>12,13</sup> Persons with laboratory-confirmed SARS-CoV-2 infection  
27    (index cases) were identified from SARS-CoV-2 clinical real-time reverse transcription  
28    polymerase chain reaction (rRT-PCR) tests conducted at Vanderbilt University Medical Center  
29    (VUMC; Nashville, Tennessee) and Marshfield Clinic Health System (MCHS; Marshfield,  
30    Wisconsin). VUMC is a large healthcare provider system serving patients from Tennessee and  
31    the Mid-South US. For this study, VUMC enrolled patients presenting to the network of walk-in-  
32    clinics that operate within Davidson County and surrounding areas. MCHS is a large  
33    community-based, multispecialty healthcare system serving predominantly rural populations in  
34    central, northern, and western Wisconsin. For this study, participants were recruited from MCHS  
35    locations in central and western Wisconsin. All or most schools in the study area were closed to  
36    in-person attendance in Spring 2020. In Fall 2020, some schools (public and private in  
37    Wisconsin and private in Tennessee) were open for full-time in-person attendance or had hybrid  
38    modalities (combination of in-person/remote attendance). SARS-CoV-2 testing capacity at both  
39    sites varied throughout the study period. Testing was limited in Spring 2020, increased by  
40    Summer 2020, with return times for results taking longer during periods with high level of  
41    community transmission. By Fall 2020, SARS-CoV-2 testing services were readily available  
42    with rapid return of results (same or next day in most cases).<sup>14</sup>

43    Index cases and their household contacts were followed daily for 14 days to ascertain symptoms  
44    and secondary transmission events. Household members were eligible if the index case had  
45    symptom onset <7 days before enrollment and there was  $\geq 1$  other household member without

46 symptoms at the time of the index case's illness onset. The primary case was the person with  
47 laboratory-confirmed SARS-CoV-2 infection in the household with the earliest illness onset date  
48 (or date of positive SARS-CoV-2 sample, if asymptomatic). This analysis included households  
49 enrolled between April 21, 2020 and April 30, 2021.

50 **Data and sample collection.** Data were primarily collected through self- or parent-administered  
51 paper (Wisconsin) or web-based surveys (Tennessee); some data were obtained through  
52 interviews with participants. At enrollment, the survey assessed demographic and household  
53 characteristics, pre-existing medical conditions, occupational risk (e.g., employed in healthcare  
54 setting or customer service), symptoms prior to enrollment, and type and frequency of  
55 interactions with other household members. Each day during the 14-day follow-up period,  
56 participants were asked about current symptoms and provided a (self- or parent-collected)  
57 respiratory (anterior nasal) and/or saliva sample for SARS-CoV-2 rRT-PCR testing regardless of  
58 symptoms. Symptoms assessed included: constitutional symptoms (chills, fatigue or feeling run  
59 down, fever or feverishness, muscle or body aches), upper respiratory symptoms (nasal  
60 congestion, runny nose, sore throat), lower respiratory symptoms (chest tightness or pain, cough,  
61 trouble breathing or shortness of breath, wheezing), neurologic symptoms (headache, loss of  
62 taste or smell), and gastrointestinal symptoms (abdominal pain, diarrhea, vomiting). All  
63 participants were asked about all symptoms except gastrointestinal, which was only included in  
64 Wisconsin.

65 **Laboratory.** Respiratory and saliva samples were tested using Center for Disease Control and  
66 Prevention (CDC), Quidel Lyra, or ThermoFisher Taq Path SARS-CoV-2 rRT-PCR assays and  
67 protocols at MCHS' Research Institute or VUMC.<sup>15-17</sup>

68 **Analysis.** Participants were grouped by age reflecting potential exposure risk and behavioral  
69 characteristics: preschool-aged (0-4 years), primary school-aged (5-11 years), secondary school-  
70 aged (12-17 years), young adults (18-49 years), middle-aged adults (50-64 years), and older  
71 adults ( $\geq 65$  years).

72 Differences among age groups were assessed using Chi-square test or Kruskal-Wallis test, where  
73 appropriate. Secondary SARS-CoV-2 infections were defined as household contacts with  $\geq 1$   
74 rRT-PCR positive sample (respiratory or saliva) with illness onset or first positive sample date  
75 within 14 days after the illness onset (or date of first positive sample, if asymptomatic) in the  
76 primary case. Secondary infection risks (SIR) were estimated using generalized estimating  
77 equations (GEE, log-binomial model), accounting for household clustering. We estimated SIR 1)  
78 by age of the primary case to assess transmission risk (the probability of transmission from the  
79 primary case to contacts), 2) by age of the contacts to assess infection risk (the probability of  
80 infection among contacts), 3) by age of the primary case and age of the contacts, and 4) by  
81 whether the primary case and contact were in the same or different age group. Risk ratios (RR)  
82 and 95% confidence intervals (CI) were used to compare SIR in each primary and contact age  
83 group versus age 18-49 years (referent) and same versus different age groups. Households with  
84  $\geq 1$  co-primary cases (household members positive for SARS-CoV-2 that had illness onset within  
85 2 days after illness onset in the primary case) were excluded.

86 We assessed frequency, sequence, and duration of symptoms by age group among participants  
87 with SARS-CoV-2 infection whose illness onset or first positive sample (if asymptomatic)  
88 occurred after study enrollment. Associations between age group and presence of specific  
89 categories of symptoms were assessed using logistic regression models. Odds ratios (OR) and  
90 95% CI were used to compare odds of symptoms in each age group versus age 18-49 years

91 (referent). Neurologic symptoms were not assessed in children aged 0-4 years, as these  
92 symptoms are difficult to ascertain in young children. Analysis of symptom duration and interval  
93 (in days) between symptom onset and first positive sample was restricted to symptomatic  
94 infections. Analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC).  
95 The study protocol was approved by Institutional Review Boards at VUMC and MCHS. CDC  
96 determined this activity was conducted consistent with applicable federal law and CDC policy  
97 (see 45 C.F.R. part 46; 21 C.F.R. part 56).

98

## 99 **RESULTS**

100 **Participant characteristics.** From April 2020 through April 2021, 302 index patients and their  
101 577 household members were enrolled. The index patient was the primary case for 96% of  
102 households. The primary analysis included 226 of 302 (75%) households with 404 contacts.  
103 Reasons for exclusion included: receipt of COVID-19 vaccine before enrollment (n=28) or  
104 contacts of a vaccinated primary case (n=4), illness onset >10 days before enrollment (n=15) as  
105 infections may have become undetectable, illness onset before the primary case without  
106 laboratory-confirmed SARS-CoV-2 infection (n=16), <6 follow-up days with survey data (n=8)  
107 or <6 follow-up days with samples with rRT-PCR results (n=14), co-primary case (n=56) or  
108 contacts in households with a co-primary case (n=46), and no remaining eligible household  
109 contacts after other exclusions (n=62 primary cases; Fig 1).

110 The majority of primary cases were non-Hispanic White young adults with a preponderance of  
111 females (Table 1). Median age was 37 years (range: 1-76 years). An underlying medical  
112 condition was reported by 81 (36%), of whom 29 (36%) had asthma. Among adults, 20%  
113 reported working in a healthcare setting and had regular face-to-face contact with sick people



114 and 19% in customer service with regular face-to-face contact with people. Most primary cases  
115 (83%) lived in a single-family home with mean of 3.2 bedrooms and mean of 3.3 members.  
116 Among those who reported on interactions with other household members, interactions  
117 decreased from the day before illness onset to the day before enrollment; 73% reported physical  
118 contact with  $\geq 1$  other household member the day before illness onset versus 38% the day before  
119 enrollment (Table 1). Masking when interacting with other members was uncommon before  
120 illness onset (6%) and 26% reported mask use the day before enrollment.

121 Children aged 0-4 years and adults aged  $\geq 65$  years represented a minority (5% and 6%,  
122 respectively) of household contacts (Table 2). Other characteristics were similar to those  
123 reported among primary cases.

124 **Transmission from primary cases and infection among contacts.** The 226 primary cases were  
125 followed by 198 (49%) SARS-CoV-2 infections among 404 household contacts. At least one  
126 contact was infected in 58% (130 of 226) of households. Estimated SIR ranged from 26% among  
127 contacts of primary cases aged 12-17 years to 76% among contacts of primary cases aged  $\geq 65$   
128 years (Fig 2). Compared to when the primary case was aged 18-49 years, SIR in household  
129 contacts was significantly lower when the primary case was aged 12-17 years (RR 0.42; 95% CI  
130 0.19-0.91), and not significantly different for all other primary case age groups. There were no  
131 significant differences in estimated SIR by age of the contacts (Fig 2). SIR ranged from 36%  
132 among contacts aged  $\geq 65$  years to 53% among contacts aged 5-11 years.

133 Overall, estimated SIR was higher when primary case-contact pairs were in the same versus  
134 different age groups (55% versus 45%, RR 1.47; 95% CI 0.98-2.22; Fig 2). SIR was highest  
135 among primary case-contacts pairs aged  $\geq 65$  years (76%) and 5-11 years (69%). Within each  
136 primary case age group, SIR was generally lowest among contacts aged  $\geq 65$  years (Fig 3).

137 However, CIs were wide for all primary case-contact age group combinations, particularly those  
138 aged <12 years.

139 **Symptoms among contacts with SARS-CoV-2 infection.** Among 186 contacts with SARS-  
140 CoV-2 infection with symptom onset or first positive rRT-PCR result after enrollment, 96%  
141 completed symptom surveys on  $\geq 13$  days of follow-up (Table 3). Most (81%) reported  $\geq 1$   
142 symptoms and 19% reported no symptoms (asymptomatic) (Fig 4). There were no differences in  
143 asymptomatic infections by age group (ranging from 12% among those aged 50-64 years to 27%  
144 among those aged 5-11 years). Among the 150 symptomatic infections, 46% were rRT-PCR  
145 positive (from nasal or saliva sample) before symptom onset. Median days from first positive  
146 viral detection to symptom onset was 2 (interquartile range [IQR] 1-3) and did not differ by age  
147 group ( $P=0.90$ ). Median number of days with a positive rRT-PCR result (from nasal samples)  
148 during follow-up was 8 (IQR 4-11); however, 34% continued to be positive on the last day of  
149 follow-up.

150 Among infected children, the most commonly reported symptoms were upper respiratory  
151 symptoms (88% aged 0-4 years, 62% aged 5-11 years, and 77% aged 12-17 years; Fig 4). Lower  
152 respiratory symptoms were reported by 68% (28 of 41) of adults aged  $\geq 50$  years (76% aged 50-  
153 64 years, 56% aged  $\geq 65$  years). Gastrointestinal symptoms were less common than other  
154 symptoms (40%) and not typically reported on the day of illness onset, but was commonly  
155 reported in children aged 5-11 years (50%) and adults aged 18-49 years (60%). Frequency and  
156 duration of individual symptoms are shown in Supplemental Fig.

157 Median duration of any symptom was 8 days (IQR 3-11) and did not differ by age group; 34%  
158 reported symptoms on the last day of follow-up and thus their symptom duration was  
159 foreshortened. However, median duration of constitutional symptoms was significantly different

160 and increased with age, from 2 days in younger children (age <12 years) to 9 days in adults aged  
161  $\geq 65$  years ( $P=0.03$ ). Median duration of neurologic symptoms was  $\leq 4$  days for all age groups  
162 except adults aged 50-64 years, where median of 10 days was observed ( $P=0.002$ ).

163

## 164 **DISCUSSION**

165 This prospective study examined the association of age with household transmission of SARS-  
166 CoV-2, addressing both age of the primary case (transmission risk) and ages of household  
167 contacts (susceptibility). With frequent and systematic testing among household contacts, we  
168 found much higher infection risks among household contacts than prior studies, similar rates of  
169 infection among child and adult household contacts, and some nuanced differences in  
170 transmission from specific age groups. However, transmission to household contacts was  
171 observed from primary cases in all age groups.

172 There is considerable heterogeneity in the literature on transmission from and susceptibility of  
173 children to SARS-CoV-2. Our finding of similar infection risk across age groups is consistent  
174 with larger investigations of reported cases from Spain,<sup>18</sup> China,<sup>6</sup> and Brunei<sup>19</sup> and other  
175 household transmission studies conducted in the US.<sup>20</sup> However, several studies have reported  
176 that children had reduced susceptibility to SARS-CoV-2 infection<sup>21-24</sup> and one found higher risk  
177 in children compared with young adults.<sup>25</sup> Difference in methods for ascertaining and detecting  
178 SARS-CoV-2 infection among household contacts may account for some of the differences  
179 between studies. Infrequent or delayed testing, or limited testing of asymptomatic/mildly-  
180 symptomatic individuals could contribute to underestimation of SARS-CoV-2 infections and  
181 may differentially impact infection risk measurements among children, thus biasing the  
182 association between age and susceptibility and transmission.

183 Additionally, some prior studies did not disaggregate age into finer age groups, analyzing all  
184 children aged <18 years together,<sup>5,9,20,24,26-29</sup> which may obscure biological or behavioral  
185 characteristics that vary by age. We categorized our study participants into six age groups,  
186 roughly aligned with US groupings in school (preschool, primary school, and secondary school)  
187 and adulthood periods (young, middle-aged, and older adults). In doing so, we found that  
188 transmission risk was highest from primary cases aged  $\geq 65$  years and lowest from primary cases  
189 aged 12-17 years. Studies from Ontario and Denmark also found transmission risk in children  
190 was highest among the youngest and lowest in adolescents.<sup>30,31</sup> Age-specific differences in  
191 behavior likely contributed to lower transmission from adolescents relative to younger, less  
192 autonomous, children.

193 Other studies have also identified somewhat increased transmission risk among contacts of  
194 similar age, and this may have implications beyond the household.<sup>31,32</sup> Transmission patterns  
195 may be influenced by assortative mixing, where similar aged people interact more with each  
196 other than with different aged people.<sup>33,34</sup> These findings may inform planning for school-based  
197 countermeasures to reduce transmission risk within and between classrooms. However, further  
198 investigation is needed to better understand how behaviors and interactions differ by age, during  
199 periods of illness, and whether those differences are associated with risk of transmission in both  
200 the household and school settings.

201 In this study and others,<sup>1</sup> young children aged <12 years were rarely identified as the primary  
202 case of SARS-CoV-2 infection in households. However, when a young child was the primary  
203 case, we saw that they transmitted infection to more than 37% of their household contacts,  
204 including adults, and their probability of transmission in the household setting was not  
205 significantly different than transmission from young adults. Similar rates of transmissibility

206 between children and adults were also found in studies conducted in China and South Korea,<sup>21,35</sup>  
207 though small sample size in young children also limited those studies.

208 The frequency and duration of symptoms were similar across age groups among those who were  
209 infected in our study. Clinical data from non-hospitalized infected children are limited, with few  
210 studies directly comparing symptoms of children and adults.<sup>5,20,36,37</sup> There were no significant  
211 differences in the frequency of asymptomatic infections between children and adults. The overall  
212 percentage of infected participants reporting no symptoms is generally consistent with the 20%  
213 estimated in a recent review and meta-analysis.<sup>38</sup> Additional studies to better understand the  
214 frequency of asymptomatic infections by age and the role of asymptomatic infection and age in  
215 onward transmission in household and community settings are needed to inform public health  
216 recommendations.

217 This study has several limitations. First, delayed identification of index cases prevented complete  
218 capture of transmission events. Participants may have become infected, but remain  
219 asymptomatic, between the time the index case was tested and study enrollment. Thus, duration  
220 of positivity and symptoms captured during the enrollment period may be subject to both right  
221 and left censoring and may be an underestimate. Second, we assumed secondary infections  
222 among contacts resulted from household exposure rather than community transmission. Ongoing  
223 exposure from the community may lead to an overestimation of transmission in household  
224 settings, especially among age groups more likely to be exposed outside the household. Although  
225 patients were instructed to isolate at home or quarantine while waiting for results,<sup>39</sup> compliance  
226 may have declined as the pandemic progressed. Third, we did not account for reported  
227 interactions between the primary case and contacts before and during illness in the primary case.  
228 While physical contact between the primary case and household contacts was common, mask use

229 by the primary case was not common before or after illness onset. Differences in age-related  
230 interactions may explain or help clarify associations between age and transmission events.  
231 Fourth, the study population was largely non-Hispanic White, and findings may not be  
232 generalizable to other racial and ethnic groups. Finally, small sample size limited the precision of  
233 estimates of SIR and our statistical power to detect true differences in transmission risk and  
234 symptom profiles by age. Despite these limitations, the case-ascertained household study  
235 described provides much needed evidence regarding susceptibility to SARS-CoV-2 infection, as  
236 exposure within the household is well-defined and prolonged. Additionally, daily follow-up  
237 allowed us to assess symptoms throughout the course of illness.

238 In conclusion, we observed that both children and adults of all ages can transmit and are  
239 susceptible to SARS-CoV-2 infection. There were no significant differences in susceptibility to  
240 SARS-CoV-2 by age group, from preschool-aged children through older adults. Further research  
241 is needed to understand age-related interactions and behaviors in households as it relates to the  
242 probability of transmission by age.

### **Acknowledgements**

We thank the following for their contributions to the study: Lynn Ivacic, Hannah Berger, Vicki Moon, Keegan Brighton, Gina Burbey, Deanna Cole, Leila Deering, Eric DeJarlais, Heather Dirkx, Sherri Guzinski, Joshua Hebert, Linda Heeren, Erin Higdon, Jacob Johnston, Chris Kadolph, Taylor Kent, Burney Kieke, Tamara Kronenwetter Koepel, Sarah Kohn, Diane Kohnhorst, Erik Kronholm, Stacey Kyle, Jim Linneman, Carrie Marcis, Karen McGreevey, Sudha Medabalimi, Nidhi Mehta, Nan Pan, Cory Pike, Rebecca Pilsner, DeeAnn Polacek, Martha Presson, Carla Rottscheit, Jacklyn Salzwedel, Kristin Seyfert, Tapan Sharma, Alyssa Spoerl, Sandy Strey, Krishna Chaitanya Upadhyay, Gail Weinand, and Benjamin Zimmerman at Marshfield Clinic Research Institute; Judy King, Dayna Wyatt, Robert Lyons, Carleigh Frazier, Emily Jookar, Karen Malone, Olivia Doak, Sarah Davis, Jorge Celedonio, Marcia Blair, Rendie McHenry, Claudia Guevara, Jennifer Luther, Laura Short, and Ahra Kim at Vanderbilt University Medical Center.

## References


1. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. *JAMA Pediatr* 2021;175:143-56.
2. Goldstein E, Lipsitch M, Cevik M. On the effect of age on the transmission of SARS-CoV-2 in households, schools, and the community. *J Infect Dis* 2021;223:362-9.
3. Spielberger BD, Goerne T, Geweniger A, Henneke P, Elling R. Intra-household and close-contact SARS-CoV-2 transmission among children - a systematic review. *Front Pediatr* 2021;9:613292.
4. Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. *JAMA Netw Open* 2020;3:e2031756.
5. Yousaf AR, Duca LM, Chu V, et al. A prospective cohort study in non-hospitalized household contacts with SARS-CoV-2 infection: symptom profiles and symptom change over time. *Clin Infect Dis* 2020.
6. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* 2020;20:911-9.
7. Accorsi EK, Qiu X, Rumpler E, et al. How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19. *Eur J Epidemiol* 2021;36:179-96.
8. Mehta NS, Mytton OT, Mullins EWS, et al. SARS-CoV-2 (COVID-19): what do we know about children? A systematic review. *Clin Infect Dis* 2020;71:2469-79.
9. Liguoro I, Pilotto C, Bonanni M, et al. SARS-COV-2 infection in children and newborns: a systematic review. *Eur J Pediatr* 2020;179:1029-46.
10. Havers FP, Whitaker M, Self JL, et al. Hospitalization of adolescents aged 12-17 years with laboratory-confirmed COVID-19 - COVID-NET, 14 States, March 1, 2020-April 24, 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:851-7.
11. Estimated disease burden of COVID-19. 2021. (Accessed June 28, 2021, at <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html>.)
12. Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-COV-2 infections in households - Tennessee and Wisconsin, April-September 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1631-4.
13. Rolfes MA, Grijalva CG, Zhu Y, et al. Implications of shortened quarantine among household contacts of index patients with confirmed SARS-CoV-2 infection - Tennessee and Wisconsin, April-September 2020. *MMWR Morb Mortal Wkly Rep* 2021;69:1633-7.
14. COVID-19: get tested. 2021. (Accessed 7/19, 2021, at <https://www.dhs.wisconsin.gov/covid-19/testing.htm>.)
15. Centers for Disease Control and Prevention. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. 2020.
16. Quidel Corporation. Lyra® SARS-CoV-2 assay instructions for use. 2020.




17. ThermoFisher Scientific. TaqPath™ COVID-19 combo kit and TaqPath™ COVID-19 combo kit advanced\* instructions for use. 2020.
18. Arnedo-Pena A, Sabater-Vidal S, Meseguer-Ferrer N, et al. COVID-19 secondary attack rate and risk factors in household contacts in Castellon (Spain): preliminary report. *Rev Enf Emerg* 2020;19:64-70.
19. Chaw L, Koh WC, Jamaludin SA, Naing L, Alikhan MF, Wong J. Analysis of SARS-CoV-2 transmission in different settings, Brunei. *Emerg Infect Dis* 2020;26:2598-606.
20. Laws RL, Chancey RJ, Rabold EM, et al. Symptoms and transmission of SARS-CoV-2 among children - Utah and Wisconsin, March-May 2020. *Pediatrics* 2021;147.
21. Hu S, Wang W, Wang Y, et al. Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. *Nat Commun* 2021;12:1533.
22. Li F, Li YY, Liu MJ, et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. *Lancet Infect Dis* 2021;21:617-28.
23. Dattner I, Goldberg Y, Katriel G, et al. The role of children in the spread of COVID-19: using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children. *PLoS Comput Biol* 2021;17:e1008559.
24. Jing QL, Liu MJ, Zhang ZB, et al. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. *Lancet Infect Dis* 2020;20:1141-50.
25. Liu T, Liang W, Zhong H, et al. Risk factors associated with COVID-19 infection: a retrospective cohort study based on contacts tracing. *Emerg Microbes Infect* 2020;9:1546-53.
26. Cheng HY, Jian SW, Liu DP, et al. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. *JAMA Intern Med* 2020;180:1156-63.
27. Lewis NM, Chu VT, Ye D, et al. Household Transmission of SARS-CoV-2 in the United States. *Clin Infect Dis* 2020.
28. Luo L, Liu D, Liao X, et al. Contact settings and risk for transmission in 3410 close contacts of patients with COVID-19 in Guangzhou, China : a prospective cohort study. *Ann Intern Med* 2020;173:879-87.
29. Wang Y, Tian H, Zhang L, et al. Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Glob Health* 2020;5.
30. Paul LA, Daneman N, Schwartz KL, et al. Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection. *JAMA Pediatr* 2021.
31. Lyngse FP, Mølbak K, Træholt Frank K, Nielsen C, Skov RL, Kirkeby CT. Association between SARS-CoV-2 transmission risk, viral load, and age: a nationwide study in Danish households. *medRxiv* 2021.

32. Laxminarayan R, Wahl B, Dudala SR, et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states. *Science* 2020;370:691-7.
33. Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. *PLoS Med* 2008;5:e74.
34. Hoang T, Coletti P, Melegaro A, et al. A systematic review of social contact surveys to inform transmission models of close-contact infections. *Epidemiology* 2019;30:723-36.
35. Park YJ, Choe YJ, Park O, et al. Contact tracing during coronavirus disease outbreak, South Korea, 2020. *Emerg Infect Dis* 2020;26:2465-8.
36. CDC COVID-19 Response Team. Coronavirus disease 2019 in children - United States, February 12-April 2, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:422-6.
37. Chung E, Chow EJ, Wilcox NC, et al. Comparison of symptoms and RNA levels in children and adults with SARS-CoV-2 infection in the community setting. *JAMA Pediatr* 2021.
38. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLoS Med* 2020;17:e1003346.
39. Coronavirus disease 2019 (COVID-19) patient testing. 2021. (Accessed 7/19, 2021, at <https://www.marshfieldclinic.org/patient-resources/patient-testing>.)


**Figure 1.** Households and individuals enrolled in a prospective study of SARS-CoV-2 household transmission — Tennessee and Wisconsin, April 2020–April 2021.




**Figure 2.** Estimated transmission risk from the primary case and infection risk among household contacts by age — Prospective study of SARS-CoV-2 household transmission, Tennessee and Wisconsin, April 2020–April 2021.



**Figure 3.** Estimated secondary infection risk by age of the primary case and age of the household contacts — Prospective study of SARS-CoV-2 household transmission, Tennessee and Wisconsin, April 2020–April 2021.



**Figure 4.** Reported symptoms, timing, and duration of symptoms by age group among persons with SARS-CoV-2 infection in a prospective study of SARS-CoV-2 household transmission — Tennessee and Wisconsin, April 2020–April 2021.



Abbreviation: OR, odds ratio; CI, confidence interval; IQR, interquartile range

<sup>6</sup>P value from Kruskal-Wallis Test comparing median days reporting symptom across age groups.

Number of cases in each age group for evaluation of all symptom categories except gastrointestinal symptoms: age 0-4 years (n=8), 5-11 years (n=26), 12-17 years (n=30), 18-49 years (n=81), 50-64 years (n=25), ≥65 years (n=16), all ages (n=186)

Number of cases in each age group for evaluation of gastrointestinal symptoms: age 0-4 years (n=7), 5-11 years (n=10), 12-17 years (n=16), 18-49 years (n=10), 50-64 years (n=10), ≥65 years (n=4), all ages (n=57)

<sup>1</sup>Upper respiratory symptoms included nasal congestion, runny nose, sore throat

<sup>2</sup>Constitutional symptoms included chills, fatigue or feeling run down, fever or feverishness, muscle or body aches

<sup>3</sup>Neurologic symptoms included headache, loss of taste or smell

<sup>4</sup>Lower respiratory symptoms included chest tightness or pain, cough, trouble breathing or shortness of breath, wheezing

<sup>5</sup>Gastrointestinal symptoms included abdominal pain, diarrhea, vomiting and were assessed only for Wisconsin participants

<sup>6</sup>Measure of association between age group and odds of symptom reported during follow-up

<sup>7</sup>Among contacts who reported the specific symptom

**Table 1.** Characteristics of primary cases by age group at enrollment in a prospective study of SARS-CoV-2 household transmission — Tennessee and Wisconsin, April 2020–April 2021

	Age						
	0-4 years	5-11 years	12-17 years	18-49 years	50-64 years	≥65 years	All ages
<b>N (row %)</b>	2 (0.9)	4 (1.8)	25 (11.1)	141 (62.4)	37 (16.4)	17 (7.5)	226 (100)
<b>Female</b>	2 (100)	0 (0)	15 (60)	81 (57)	21 (57)	9 (53)	128 (56.6)
<b>Race/ethnicity<sup>1</sup></b>							
<b>Non-Hispanic White</b>	---	---	23 (92)	115 (82)	35 (95)	17 (100)	194 (85.8)
<b>Non-Hispanic other race</b>	---	---	0	9 (6)	1 (3)	0	11 (4.9)
<b>Hispanic or Latino</b>	---	---	2 (8)	16 (11)	1 (3)	0	20 (8.9)
<b>Smoker (aged ≥18 years)</b>	---	---	---	7 (5)	2 (5)	0	9 (5)
<b>Any underlying medical conditions<sup>3</sup></b>	1 (50)	0	9 (36)	46 (33)	13 (35)	12 (71)	81 (35.8)
<b>Occupational, school, or childcare exposures</b>							
<b>Attended childcare or school outside home<sup>4</sup> (aged &lt;18 years)</b>	1 (100)	3 (100)	14 (74)	---	---	---	18 (78)
<b>Healthcare setting (aged ≥18 years)<sup>4,5</sup></b>	---	---	---	33 (24)	6 (16)	0	39 (20)
<b>Customer service (aged ≥18 years)<sup>4,5</sup></b>	---	---	---	31 (22)	4 (11)	2 (12)	37 (19)
<b>Teacher (aged ≥18 years)<sup>4</sup></b>	---	---	---	4 (4)	2 (7)	1 (8)	7 (5)
<b>Household characteristics</b>							
<b>Mean (SD) number of household members<sup>6</sup></b>	4.0 (0)	4.3 (1.7)	4.4 (0.9)	3.4 (1.4)	2.7 (0.8)	2.1 (0.2)	3.3 (1.4)
<b>Type of home</b>							
<b>Single family home</b>	2 (100)	3 (75)	25 (100)	110 (78)	33 (89)	14 (82)	187 (82.7)
<b>Duplex / townhome</b>	0	0	0	8 (6)	0	0	8 (3.5)
<b>Condo / apartment building</b>	0	1 (25)	0	23 (16)	4 (11)	3 (18)	31 (13.7)
<b>Mean (SD) number of bedrooms<sup>6</sup></b>	4.0 (0)	3.3 (1.0)	3.9 (0.7)	3.0 (1.0)	3.4 (1.2)	2.9 (0.7)	3.2 (1.0)
<b>Interactions with other household members<sup>4,7</sup></b>							
<b>Maximum time spent in same room with ≥1 other member</b>							
<b>Day before illness onset</b>							
<b>&gt;4 hours</b>	2 (100)	2 (100)	10 (43)	56 (59)	10 (40)	6 (60)	86 (55)
<b>1-4 hours</b>	0	0	7 (30)	23 (24)	11 (44)	1 (10)	42 (27)
<b>&lt;1 hour</b>	0	0	3 (13)	16 (17)	4 (16)	3 (30)	26 (17)
<b>No time</b>	0	0	3 (13)	0	0	0	3 (2)
<b>Day before enrollment</b>							
<b>&gt;4 hours</b>	2 (100)	1 (50)	4 (17)	35 (37)	6 (23)	2 (20)	50 (32)
<b>1-4 hours</b>	0	0	7 (30)	15 (16)	6 (23)	3 (30)	31 (20)
<b>&lt;1 hour</b>	0	1 (50)	8 (35)	26 (27)	7 (27)	4 (40)	46 (29)
<b>No time</b>	0	0	4 (17)	19 (20)	7 (27)	1 (10)	31 (20)



	Age						
	0-4 years	5-11 years	12-17 years	18-49 years	50-64 years	≥65 years	All ages
<b>Had physical contact with ≥1 other members</b>							
<b>Day before illness onset</b>	2 (100)	2 (100)	15 (75)	69 (73)	19 (73)	5 (56)	112 (73)
<b>Day before enrollment</b>	2 (100)	1 (50)	6 (32)	37 (46)	3 (14)	2 (22)	51 (38)
<b>Slept in the same room with ≥1 other members</b>							
<b>Day before illness onset</b>	0	1 (50)	3 (15)	43 (45)	12 (46)	5 (50)	64 (41)
<b>Day before enrollment</b>	0	0	1 (5)	29 (36)	5 (24)	2 (22)	37 (28)
<b>Frequency of masking when interacting with ≥1 other members</b>							
<b>Day before illness onset</b>							
<b>Never</b>	1 (100)	---	7 (88)	44 (98)	15 (83)	9 (100)	76 (94)
<b>Sometimes</b>	0	---	1 (13)	1 (2)	3 (17)	0	5 (6)
<b>Always</b>	0	---	0	0	0	0	0
<b>Day before enrollment</b>							
<b>Never</b>	1 (100)	---	5 (63)	33 (79)	11 (65)	7 (78)	57 (74)
<b>Sometimes</b>	0	---	2 (25)	3 (7)	1 (6)	0	6 (8)
<b>Always</b>	0	---	1 (13)	6 (14)	5 (29)	2 (22)	14 (18)

Data are no. (% of column total with response) unless otherwise noted, numbers reflect rounding

Abbreviation: SD, standard deviation

<sup>1</sup>Unknown for 1 participant

<sup>2</sup>Data suppressed to protect privacy

<sup>3</sup>Underlying medical conditions included: asthma, cancer, cardiovascular or heart disease, diabetes, extreme obesity, high blood pressure or hypertension, immunocompromising condition, kidney disease, liver disease, other chronic lung disease, pregnancy, and prematurity

<sup>4</sup>Missing responses

<sup>5</sup>Healthcare setting were those who reported working in a healthcare setting and having regular face-to-face contact with sick people, customer service were those who reported working in customer service where they have regular face-to-face contact with people

<sup>6</sup>Data presented in this row are mean and standard deviation

<sup>7</sup>Restricted to primary cases who were also the index case in the household

**Table 2.** Characteristics of household contacts by age group at enrollment in a prospective study of SARS-CoV-2 household transmission — Tennessee and Wisconsin, April 2020–April 2021

	Age						All ages
	0-4 years	5-11 years	12-17 years	18-49 years	50-64 years	≥65 years	
<b>N (row %)</b>	21 (5.2)	53 (13.1)	67 (16.6)	184 (45.5)	53 (13.1)	26 (6.4)	404 (100)
<b>Female</b>	9 (43)	25 (47)	28 (42)	98 (53)	28 (53)	13 (50)	201 (49.8)
<b>Race/Ethnicity</b>							
<b>Non-Hispanic White</b>	19 (90)	40 (75)	55 (82)	148 (80)	48 (91)	24 (92)	334 (82.7)
<b>Non-Hispanic other race</b>	1 (5)	2 (4)	4 (6)	19 (10)	1 (2)	2 (8)	29 (7.2)
<b>Hispanic or Latino</b>	1 (5)	11 (21)	8 (12)	17 (9)	4 (8)	0	41 (10.2)
<b>Smoker (aged ≥18 years)</b>	---	---	---	12 (7)	3 (6)	0	15 (6)
<b>Any underlying medical conditions<sup>1</sup></b>	0	6 (11)	15 (22)	53 (29)	17 (32)	16 (62)	107 (26.5)
<b>Occupational, school, or childcare exposures</b>							
<b>Attended childcare or school outside home<sup>2</sup> (aged &lt;18 years)</b>	5 (56)	21 (66)	29 (71)	---	---	---	55 (67)
<b>Healthcare setting (aged ≥18 years)<sup>2,3</sup></b>	---	---	---	17 (9)	5 (9)	1 (4)	23 (8.8)
<b>Customer service (aged ≥18 years)<sup>2,3</sup></b>	---	---	---	36 (20)	10 (19)	2 (8)	48 (18.5)
<b>Teacher (aged ≥18 years)<sup>2</sup></b>	---	---	---	8 (6)	2 (5)	1 (5)	11 (5.5)

Data are no. (% of column total with response) unless otherwise noted, numbers reflect rounding

<sup>1</sup>Underlying medical conditions included: asthma, cancer, cardiovascular or heart disease, diabetes, extreme obesity, high blood pressure or hypertension, immunocompromising condition, kidney disease, liver disease, other chronic lung disease, pregnancy, and prematurity

<sup>2</sup>Missing responses

<sup>3</sup>Healthcare setting were those who reported working in a healthcare setting and having regular face-to-face contact with sick people, customer service were those who reported working in customer service where they have regular face-to-face contact with people



**Table 3.** Characteristics of contacts with SARS-CoV-2 infection included in symptom analysis by age group — Prospective study of SARS-CoV-2 household transmission, Tennessee and Wisconsin, April 2020–April 2021

	0-4 years	5-11 years	12-17 years	18-49 years	50-64 years	≥65 years	All ages
<b>N (row %)</b>	8 (4)	26 (14)	30 (16)	81 (44)	25 (13)	16 (9)	186 (100)
<b>Female, n (column %)</b>	3 (38)	11 (42)	15 (50)	36 (44)	11 (44)	10 (63)	86 (46)
<b>Race/ethnicity, n (column %)</b>							
<b>Non-Hispanic White</b>	8 (100)	20 (77)	24 (80)	63 (78)	23 (92)	16 (100)	154 (83)
<b>Non-Hispanic other race</b>	0	0	2 (7)	8 (10)	0	0	10 (5)
<b>Hispanic or Latino</b>	0	6 (23)	4 (13)	10 (12)	2 (8)	0	22 (12)
<b>Smoker (aged ≥18 years), n (column %)</b>	---	---	---	2 (2)	1 (4)	0	3 (2)
<b>Any underlying medical conditions<sup>1</sup>, n (column %)</b>	0	2 (8)	1 (3)	20 (25)	9 (36)	10 (63)	42 (23)
<b>Occupational, school, or childcare exposures, n (column %)</b>							
<b>Attended childcare or school outside home<sup>2</sup> (aged &lt;18 years)</b>	2 (50)	15 (65)	11 (55)	---	---	---	28 (60)
<b>Healthcare setting (aged ≥18 years)<sup>2,3</sup></b>	---	---	---	6 (8)	3 (12)	1 (6)	10 (8)
<b>Customer service (aged ≥18 years)<sup>2,3</sup></b>	---	---	---	14 (18)	4 (16)	2 (13)	20 (17)
<b>Teacher (aged ≥18 years)<sup>2</sup></b>	---	---	---	4 (6)	1 (5)	1 (8)	6 (6)
<b>Completed ≥13 (of 14) symptom surveys, n (column %)</b>	8 (100)	26 (100)	29 (97)	80 (99)	24 (96)	12 (75)	179 (96)
<b>Took medication for fever or pain at least 1 day, n (column %)</b>	6 (75)	9 (35)	11 (37)	41 (51)	18 (72)	9 (56)	94 (51)
<b>Sought medical care during follow-up, n (column %)<sup>2</sup></b>	0	0	2 (7)	5 (6)	0	2 (13)	9 (5)
<b>Timing of positive result relative to symptom onset</b>							
<b>Positive rRT-PCR result before symptom onset, n (column %)<sup>4,6</sup></b>	3 (43)	11 (58)	10 (42)	30 (46)	11 (50)	4 (31)	69 (46)
<b>Median (IQR) days from first positive to symptom onset<sup>4,5,6</sup></b>	2 (1, 3)	3 (1, 3)	2 (1, 3)	1.5 (1, 3)	2 (1, 4)	2 (1, 5)	2 (1, 3)
<b>Median (IQR) days positive during follow-up period<sup>7</sup></b>	9 (6.5, 11)	8 (3.5, 10.5)	8 (6, 11)	8 (4, 11)	12 (7, 13)	8 (1, 12)	8 (4, 11)
<b>Median (IQR) days from primary case onset</b>							
<b>To first positive</b>	7 (6.5, 9)	6 (5, 9)	6 (5, 8)	6 (4, 8)	5 (5, 7)	5 (4, 5.5)	6 (4, 8)
<b>To first symptom<sup>4</sup></b>	8 (6, 8)	6 (5, 10)	6 (4.5, 9)	6 (4, 7)	6 (5, 7)	5 (4, 6)	6 (5, 8)

Abbreviation: IQR, interquartile range; rRT-PCR, real-time reverse transcription polymerase chain reaction

<sup>1</sup>Underlying medical conditions included: asthma, cancer, cardiovascular or heart disease, diabetes, extreme obesity, high blood pressure or hypertension, immunocompromising condition, kidney disease, liver disease, other chronic lung disease, pregnancy, and prematurity

<sup>2</sup>Missing responses

<sup>3</sup>Healthcare setting were those who reported working in a healthcare setting and having regular face-to-face contact with sick people, customer service were those who reported working in customer service where they have regular face-to-face contact with people

<sup>4</sup>Among contacts who reported any symptoms. Symptoms assessed included: constitutional symptoms (chills, fatigue or feeling run down, fever or feverishness, muscle or body aches), upper respiratory symptoms (nasal congestion, runny nose, sore throat), lower respiratory symptoms (chest tightness or pain, cough,

trouble breathing or shortness of breath, wheezing), neurologic symptoms (headache, loss of taste or smell), and gastrointestinal symptoms (abdominal pain, diarrhea, vomiting). Gastrointestinal symptoms were assessed in Wisconsin only

<sup>5</sup>Among contacts with a positive rRT-PCR result before symptom onset

<sup>6</sup>Impacted by left-censoring, participants may have been positive prior to their symptom onset and positive prior to the start of follow-up

<sup>7</sup>Restricted to nasal samples only; impacted by censoring (left and right)